Overview

Effect of Sitagliptin on Graft Function Following Islet Transplantation

Status:
Terminated
Trial end date:
2013-11-01
Target enrollment:
0
Participant gender:
All
Summary
Islet transplantation requires a large number of islets required to achieve insulin independence and the function of the transplanted islets progressively declines over time. Evidence from animal studies and human islets in culture suggests that increasing GLP-1 levels could help with both of these problems. This study is designed to test this hypothesis using sitagliptin in a randomized clinical trial.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
University of British Columbia
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Dipeptidyl-Peptidase IV Inhibitors
Sitagliptin Phosphate
Criteria
Inclusion Criteria:

- Type 1 diabetes for > 5 years with negative C peptide, GFR > 70 ml/min, BMI ≤ 28 and
non-smoker for ≥ 1 year

Exclusion Criteria:

- Known hypersensitivity to sitagliptin